<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Dexamethasone - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Dexamethasone</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Endocrine / Metabolic / Antidotes</div>
      <h1>Dexamethasone</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Dexamethasone 4mg Tablets</li>
          <li>Dexamethasone 4mg/mL Injection</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <p><strong>Severe allergic reaction / anaphylaxis adjunct (does not replace epinephrine)</strong></p>
        <ul>
          <li>4–10 mg IV/IM (or PO if able) as adjunct therapy; follow local protocol/medical direction</li>
        </ul>
        <p><strong>Acute asthma/COPD exacerbation (systemic steroid; protocol-dependent)</strong></p>
        <ul>
          <li>8–16 mg PO/IV once, then 4–8 mg daily for a short course (use local guidance)</li>
        </ul>
        <p><strong>Severe pharyngitis/airway inflammation (selected cases; protocol-dependent)</strong></p>
        <ul>
          <li>Single dose 8–10 mg PO/IM/IV (local guidance)</li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Anti-inflammatory / immunosuppressive steroid for selected acute conditions (protocol-dependent)</li>
          <li>Adjunct in severe allergic reactions (not first-line)</li>
          <li>Acute exacerbations of obstructive airway disease when systemic steroid indicated</li>
          <li>Other specialist-directed indications (e.g., cerebral edema) — follow medical direction</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity</li>
          <li>Untreated systemic infection (relative; risk–benefit in time-critical scenarios)</li>
          <li>Caution in: diabetes (hyperglycemia), hypertension, peptic ulcer disease/GI bleed risk, psychiatric history (mood/psychosis), glaucoma</li>
          <li>Avoid routine use without a clear indication; use shortest effective course</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Hyperglycemia</li>
          <li>Mood changes, agitation, insomnia</li>
          <li>GI upset; increased infection risk (dose/course dependent)</li>
          <li>Fluid retention, hypertension (dose dependent)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <p><strong>PO tablets</strong></p>
        <ul>
          <li>Give with food when feasible to reduce GI upset</li>
        </ul>
        <p><strong>Injection (4 mg/mL)</strong></p>
        <ul>
          <li>Administer IV/IM per product monograph/local protocol</li>
          <li>Use appropriate dilution/administration rate per local guidance</li>
        </ul>
        <p>Use the lowest effective dose and reassess need for repeat dosing</p>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Clinical response (airway symptoms, allergic symptoms)</li>
          <li>Glucose monitoring when feasible in diabetics/high-risk patients</li>
          <li>Mental status/mood changes, BP if clinically relevant</li>
          <li>Infection signs if prolonged/repeated dosing</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>If labs are limited, be conservative with repeat dosing and document indication/dose/time clearly</li>
          <li>In diabetics, anticipate hyperglycemia; plan monitoring and follow onboard diabetes protocols</li>
          <li>For allergic reactions, emphasize that dexamethasone is adjunctive—ensure core therapy and observation are addressed</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (dexamethasone injection): https://pdf.hres.ca/dpd_pm/00058006.PDF</li>
          <li>Health Canada product monograph (dexamethasone tablets): https://pdf.hres.ca/dpd_pm/00065302.PDF</li>
          <li>BCEHS drug monograph (dexamethasone): https://handbook.bcehs.ca/drug-monographs/dexamethasone/</li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
